Abstract: Provided is an apparatus, system, and method for a nested syringe assembly. The nested syringe assembly includes a first syringe having a cylindrical body defining an inner diameter and a second syringe having a cylindrical body defining an outer diameter. The outer diameter of the second syringe is less than the inner diameter of the first syringe. At least a portion of the cylindrical body of the second syringe is disposed within the cylindrical body of the first syringe.

Abstract: The use of P2X4 antagonists for the treatment of dry eye syndrome, more in particular substituted N-phenylacetamide compounds of general formula (I), pharmaceutical compositions and combinations comprising said compounds for use in the treatment or prophylaxis of dry eye syndrome and in particular dry eye, ocular neuropathic pain, ocular trauma and post-operative ocular pain.

Abstract: A syringe including a syringe body extending from a proximal end to a distal end, and a stabilizing element provided on the distal end of the syringe body, a portion of the stabilizing element extending substantially perpendicular to a longitudinal axis of the syringe body. A multi-use disposable set (MUDS) includes a plurality of syringes, each syringe having a syringe body, a proximal end, a distal end spaced apart from the proximal end along a longitudinal axis of the syringe body, a stabilizing element provided on the distal end, a portion of the stabilizing element extending substantially perpendicular to the longitudinal axis of the syringe body, and a manifold in fluid communication with the distal end of each of the plurality of syringes.

Abstract: Substituted N-phenylacetamide compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases.

Abstract: The present disclosure deals with the quickening of MRI examinations. Subjects of the present disclosure are a method, a system, a computer program product, a use, a contrast agent for use and a kit.

Abstract: A syringe for a fluid delivery system includes a pressure jacket having a distal end, a proximal end, and a throughbore therebetween. The syringe further includes a rolling diaphragm having a proximal end with an end wall for engaging a plunger, a distal end received within the throughbore of the pressure jacket. The distal end of the rolling diaphragm has a nozzle and a sidewall extending between the proximal end and the distal end of the rolling diaphragm along a longitudinal axis. At least a portion of one of the sidewall and the end wall has non-uniform thickness. At least a portion of the sidewall is flexible and rolls upon itself when acted upon by the plunger such that an outer surface of the sidewall at a folding region is folded in a radially inward direction as the plunger is advanced from the proximal end to the distal end of the rolling diaphragm.

Abstract: Provided is a method for delivering a medical fluid. The method includes delivering a fluid volume, which includes contrast and/or a flush fluid, at a preselected total volumetric flowrate during a first duration of a fluid delivery procedure. The amount of the contrast agent and the flush fluid in the fluid volume can be controllably varied during the first duration of the fluid delivery procedure so as to substantially maintain a preselected total volumetric flowrate throughout the first duration of the fluid delivery procedure. Also provided is a fluid delivery system capable of performing this method.

Abstract: The present invention aims to provide a composition for controlling Cercospora leaf spot of beet causing serious damage in beet cultivation, and a method for controlling Cercospora leaf spot of beet using the composition for controlling said disease. The present invention relates to a composition for controlling Cercospora leaf spot of beet comprising isotianil, and a method for controlling Cercospora leaf spot of beet comprising applying a composition for controlling Cercospora leaf spot of beet comprising isotianil at least once. The composition for controlling Cercospora leaf spot of beet of the present invention may further comprise a controlling agent for Cercospora leaf spot of beet other than isotianil.

Abstract: A method is provided for authenticating, and establishing and tracking eligibility of a patient to purchase an over-the-counter (OTC) drug from a retailer, the patient using a client device or terminal and the retailer having a server. The server is configured to redirect the client device or terminal to a backend platform to authenticate the patient, access a storage to search for any information that indicates the patient is ineligible to purchase the OTC drug; and without any information that indicates the patient is ineligible, administer a questionnaire to the patient to assess the eligibility for the OTC drug. And the backend platform redirects the client device or terminal back to the server to complete the online sale of the OTC drug to the patient when the patient is eligible, or cancel the online sale of the OTC drug to the patient when the patient is ineligible.

Abstract: The present invention covers an ATR kinase inhibitor, particularly 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(H-pyrazol-5-yl)-1,7-naphthyridine (“Compound A”), for use in the treatment of a hyper-proliferative disease in a subject, wherein the hyper-proliferative disease or the subject is or has been characterized by one or more biomarker(s), wherein the biomarker(s) comprise(s) a) one or more functional mutations in one or more gene(s)/protein(s) selected from RBBP8, APOBEC3A, APOBEC3B, CLSPN, ERCC, HUS1, MAD2L2, PGBD5, POLD1, RAD1, TIMELESS and/or TIPIN; and/or b) the expression of a fusion gene encoding a fusion protein selected from EWSR-ERG, EWSR1-FLI1, SS18-SSX and/or SS18-SSX2 gene/protein.

Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4, and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and prophylaxis of diseases, in particular hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Abstract: A fluid mixing device for mixing a first injection fluid and a second injection fluid includes a first fluid inlet, a second fluid inlet, a mixing chamber in fluid communication with the first and second fluid inlets, and an outlet port in fluid communication with the mixing chamber. The first fluid inlet is configured to conduct the first injection fluid in a first direction and has a first redirecting surface. The second fluid inlet is configured to conduct the second injection fluid in a second direction along a different axis from the first direction and has a second redirecting surface. The mixing chamber is configured to mix the first injection fluid and the second fluid together. The mixture of the first injection fluid and the second injection fluid exits the fluid mixing device via the outlet port.

Abstract: The present disclosure relates to azabicyclyl-substituted heterocyclic compounds of formula (I), wherein A1, A2, m, R3, R4, R5, L, R6, T, the ring Y, p, R7 and Q have the meanings as defined in the specification, to compositions comprising such compounds, to processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.

Abstract: The present invention relates to the use of 5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine (compound A), more particularly (+)5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine (compound A?), for treating diffuse large B-cell lymphoma (DLBCL), especially in germinal-centre B-cell type of diffuse large B-cell lymphoma and especially in diffuse large B-cell lymphoma which cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or an overexpression of MYC and/or BCL2.

Abstract: A pest monitoring system and associated method includes pest monitoring devices for placement at a site and generating a signal upon detection of a pest, and a pesticide dispensing unit including a reservoir housing a diluent and a pesticide module housing a pesticide. A computer device remotely disposed to the pest monitoring devices receives generated signals therefrom, analyzes environmental and historical factor data for the site to determine an amount and placement location of the pest monitoring devices for monitoring the site, and directs deployment of the pest control monitoring devices according to the analysis. The computer device also receives data from the pesticide dispensing unit including an amount or rate of the pesticide substance dispensed from the pesticide module, to form treatment having a concentration of the pesticide substance in the diluent, the treatment being dispensed from the pesticide dispensing unit to treat a detected pest at the site.

Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an inhibitor of ATR kinase, particularly an inhibitor of ATR kinase selected from VX-803, VX-970, AZD-6738, a compound of general formula (I) described herein, a compound of general formula (Ib) described herein and Compound A described infra, and component B being a PD-1/PD-L1 inhibitor described herein. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.

Abstract: The invention relates to a multi-stage process for preparing 2,6-dialkylphenylacetic acids of the general formula (I) by reacting 2,6-dialkylbromobenzenes with (1) magnesium, (2) a formamide, (3) an acid, (4) hydrogenation of the benzaldehyde obtained, (5) activation of the benzyl alcohol obtained, (6) cyanation of the activated benzyl alcohol and (7) hydrolysis of the nitrile obtained.

Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also the preparation and use of the crystalline polymorph I of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I).